Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lintitript
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lintitript is a highly specific and potent small molecule antagonist of the cholecystokinin type A (CCK-A, also known as CCK1) receptor. It was initially developed by Sanofi for the treatment of appetite disorders and investigated in clinical trials for conditions such as advanced pancreatic cancer and anorexia nervosa. By antagonizing the CCK-A receptor, lintitript blocks the effects of cholecystokinin, a neuropeptide involved in modulating feeding behavior and dopamine-induced responses in both the central and peripheral nervous systems. Although it showed promise as an appetite suppressant, development was discontinued after Phase II trials due to lack of efficacy or strategic reasons[1][2][3][4][5].
- Other names
- Lintitript [INN]136381-85-6DTXSID9046738DTXSID-9046738DTXSID 90467383YFV00531K
02
Targets
CCKAR (Cholecystokinin A receptor)
Beyond the preview
Go deeper on Lintitript.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lintitript.